




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 307/20	A1	(11) International Publication Number: WO 99/48885 (43) International Publication Date: 30 September 1999 (30.09.99)
(21) International Application Number: PCT/GB99/00852 (22) International Filing Date: 18 March 1999 (18.03.99) (30) Priority Data: 9805898.5 20 March 1998 (20.03.98) GB (71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): AL-FARHAN, Emile [US/US]; Pharm-Eco Laboratories Inc., 128 Spring Street, Lexington, MA 02421 (US). DEININGER, David, D. [US/US]; Vertex Pharmaceuticals Inc., 130 Waverly Street, Cambridge, MA 02139-4211 (US). McGHIE, Stephen [GB/GB]; (GB). O'CALLAGHAN, John [GB/GB]; Redwood, East Hill Road, Kemsing, Kent TN15 6YD (GB). ROBERTSON, Mark, Stuart [GB/GB]; (GB). RODGERS, Keith [GB/GB]; Beltinge, East Hill Road, Kemsing, Kent TN15 6YD (GB). ROUT, Stephen, John [GB/GB]; (GB). SINGH, Hardev [IN/GB]; Glaxo Wellcome plc, Temple Hill, Dartford, Kent DA1 5AH (GB). TUNG, Roger, Dennis [US/US]; Vertex Pharmaceuticals Inc., 130 Waverly Street, Cambridge, MA 02139-4211 (US).		(74) Agent: THORNLEY, Rachel, M.; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: PROCESS FOR THE SYNTHESIS OF HIV PROTEASE INHIBITORS <div style="text-align: center;">  </div> <p style="text-align: right;">(A)</p>		
(57) Abstract An improved process for the synthesis of (3S)-tetrahydro-3-furyl N-[(1S,2R)-3-(4-amino-N-isobutylbenzenesulphonamido)-1-benzyl-2-hydroxypropyl]carbamate comprising four steps from the compound of formula (A) and a novel intermediate thereto.		

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Process for the Synthesis of HIV Protease Inhibitors

This invention relates to a new process for the synthesis of (3*S*)-tetrahydro-3-furyl *N*-[(1*S*,2*R*)-3-(4-amino-*N*-isobutylbenzenesulphonamido)-1-benzyl-2-hydroxypropyl] carbamate, hereinafter referred to as the compound of formula (I), and to novel intermediates thereto.

The compound of formula (I) has the following structure



and was first described in PCT patent publication number WO94/05639 at Example 168. Currently there is considerable interest in the compound of formula (I) as a new chemotherapeutic compound in the treatment of human immunodeficiency virus (HIV) infection and the associated conditions such as acquired immune deficiency syndrome (AIDS) and AIDS dementia.


There exists at the present time a need to produce large quantities of the compound of formula (I) for clinical investigation into the efficacy and safety of the compound as a chemotherapeutic agent in the treatment of HIV infections.

An ideal route for the synthesis of the compound should produce the compound of formula (I) in high yields at a reasonable speed and at low cost with minimum waste materials and in a manner that is of minimum impact to the environment in terms of disposing of waste-materials and energy consumption.


We have found a new process for the synthesis of the compound of formula (I) with many advantages over previously known routes of synthesis. Such advantages include lower cost, less waste and more efficient use of materials. The new process enables advantageous preparation of the compound of formula (I) on a manufacturing scale.

The route of synthesis of the compound of formula (I) described in the specification of WO94/05639 is specifically described therein in examples 39A, 51A, 51B, 51C, 51D, 167 and 168. The overall yield from these examples is 33.2% of theory.

Generally the route described in WO94/05639 involves protecting the amino alcohol of formula (A) (Ex.39)




wherein P is a protecting group to form a compound of formula (B);



wherein P and P' are each independently a protecting group;

deprotecting the compound of formula (B) to form a compound of formula (C) (Ex 51A);

3




wherein P' is a protecting group;

5

forming a hydrochloride salt of compound (C) (Ex 51B) then reacting with N-imidazolyl-(S)-tetrahydrofuryl carbamate to form the compound of formula (D) (Ex 51C);

10




wherein P' is a protecting group;

15

deprotecting the compound of formula (D) (Ex 51D) wherein P' is a protecting group to form the compound of formula (D) wherein P' is H (Ex 51E); and coupling the resultant secondary amine on the compound of formula (D) to a p-nitrophenylsulphonyl group to form a compound of formula (E) (Ex 167);

4



the resultant compound of formula (E) is then reduced to form the compound of formula (I) (Ex 168).

5 In summary, the process disclosed in WO94/05639 for producing the compound of formula (I) from the compound of formula (A) comprises 6 distinct stages:

- 1) protecting,
- 2) deprotecting,
- 10 3) reacting the resultant compound with an activated tetrahydrofuranol group,
- 4) deprotecting,
- 5) coupling with a p-nitrophenylsulfonyl group, and
- 15 6) reducing the resultant compound to form a compound of formula (I).

Applicants have now found a process by which the compound of formula (I) may be prepared on a manufacturing scale from the same starting intermediate, the compound of formula (A), in only 4 distinct stages instead of 6. In addition to the
 20 associated benefits of fewer stages, such as savings in time and cost, the improved process reduces the number of waste products formed. Furthermore, product may be obtained in a higher yield, of approximately 50% of theory.

The process of the present invention involves the following steps from the
 25 compound of formula (A) to the compound of formula (I);

- 1) coupling (A) with a p-nitrophenylsulfonyl group,


5

- 2) deprotecting the resultant compound,
- 3) reacting the resultant compound with a derivative of tetrahydrofuranol, and
- 4) reducing the resultant compound to form a compound of formula (I).

5


Ideally the tetrahydrofuranol derivative is prepared and coupled with the compound resulting from step 2) in a single step.

10 Therefore, presented as a feature of the present invention is a process for the preparation of the compound of formula (I)



15 comprising:

- i) reacting a p-nitrophenylsulfonyl group with a compound of formula (A)



20

in which P is an amine-protecting group;

- ii) deprotecting the resultant compound of step (i);
- iii) reacting the resultant compound of step (ii) with a tetrahydrofuryloxy carbonyl group; or reacting the resultant compound of step ii) with phosgene, or equivalent, and reacting the resultant intermediate with (S)-tetrahydro-3-furanol; and
- 5 iv) reducing the resultant compound of step (iii) to form a compound of formula (I).

Preferably the protecting group P in the compound of formula (A) is an amine protecting group selected from alkyl, aryl, benzyl or heteryl carbamates, alkyl or aryl amides, or silyl groups. Most preferably P is a *t*-butyl carbamate.

10

Preferably step i) is carried out by treating the compound of formula (A) with a *p*-nitrophenylsulfonyl halide, preferably *p*-nitrobenzenesulfonyl chloride, in a suitable solvent selected from a ketone such as acetone, an ester such as ethyl acetate, an ether such as diethyl ether, an amine such as triethylamine, an amide such as
15 dimethylformamide or dimethylacetamide, a chlorinated solvent such as dichloromethane and other solvents such as acetonitrile or toluene or mixtures thereof. Preferably, the reaction is carried out at a temperature in the range about 30°C to reflux temperature, preferably in the range 70-90°C, with dimethylacetamide or toluene as the solvent.

20

Preferably step ii) is carried out in a suitable solvent selected from an alcohol such as ethanol, an ester such as ethyl acetate, an ether such as diethyl ether, a chlorinated solvent such as dichloromethane and other solvents such as acetonitrile or toluene or mixtures thereof. Ideally the reaction is carried out by treating a
25 solution, for example an ethanol or toluene solution, of the resultant compound of step i) with an acid or base, for example a mineral acid such as hydrochloric acid or gaseous hydrogen chloride. Ideally the reaction is carried out at a temperature in the range about 50°C to reflux temperature with hydrochloric acid. Preferably the reaction is carried out at atmospheric pressure.

30


Preferably the step ii) product is crystallised as a solvate, preferably an ethanolate, which is subsequently removed by drying. This provides advantages in yield.

The product of stage ii), (2*R*,3*S*)-*N*-(3-amino-2-hydroxy-4-phenylbutyl)-*N*-isobutyl-4-nitrobenzene sulphonamide hydrochloride and solvates thereof, are novel compounds and are presented as a further feature of the present invention.

5 Preferably step iii) is carried out by reacting the resultant compound of step ii) with a tetrahydrofuryloxy carbonyl group (prepared, for example, by reacting (S)-tetrahydro-3-furanol with 1,1'-carbonyldiimidazole, a chloroformate or phosgene), or reacting the resultant compound of step ii) with phosgene, or equivalent, to produce an isocyanate intermediate which can then react with (S)-tetrahydro-3-furanol or a
10 precursor thereof. A suitable solvent may be selected from an ester such as ethyl acetate, an amide such as dimethylformamide, a chlorinated solvent such as dichloromethane and other solvents such as acetonitrile or toluene or mixtures thereof. Ideally the reaction is carried out in a single step by reacting (S)-tetrahydro-3-furanol with 1,1'-carbonyldiimidazole and the resultant compound of step ii) in
15 ethyl acetate at a temperature in the range about 50°C to reflux temperature. Preferably the reaction is carried out at atmospheric pressure.


Preferably step iv) is carried out by treating the resultant compound of step iii) with a reducing agent, for example a noble metal catalyst such as palladium, under a
20 hydrogen atmosphere, in a suitable solvent, selected from an alcohol such as ethanol or isopropanol, a ketone such as acetone, an ester such as ethyl acetate, an amide such as dimethylformamide, and other solvents, such as tetrahydrofuran or mixtures thereof. Ideally the reaction is carried out in an alcohol, such as isopropanol, with a catalytic quantity of 5 or 10% palladium on carbon support at 0°C
25 to 60°C under a hydrogen atmosphere.

The following scheme represents the process according to the invention and is not intended to limit the scope of the invention but is provided for illustration only.



Compounds of formula (A) may be produced by the ring opening of a compound of formula (F)

5



by addition of isobutylamine.

Compounds of formula (F) are known in the art, and may be produced by the
10 methods described in Tetrahedron Letters (1995), 36 (19), 3317-20 and Tetrahedron Letters (1995), 36 (31), 5453-6.

In order that the invention may be more fully understood the following examples are presented by way of illustration only.

15

In the Intermediates and Examples unless otherwise stated:

All temperatures refer to °C. Proton Magnetic Resonance ($^1\text{H-NMR}$) spectra were recorded at 400, 500 MHz, chemical shifts are reported in ppm downfield (d) from
20 Me_4Si , used as internal standard, and are assigned as singlets (s), doublets (d), doublets of doublets (dd), triplets (t), quartets (q) or multiplets (m). The following abbreviations are used in text: THF = tetrahydrofuran, EtOH = ethanol, DMA = dimethylacetamide, TEA HCl = triethylamine hydrochloride.

Examples

Example 1

(1S,2R)-tert-butyl N-[1-benzyl-2-hydroxy-3-(isobutylamino)propyl] carbamate
5 (127.77g, 379.7mmol) was heated in toluene (888ml) to 80°C and triethylamine (42.6g, 417.8mmol) added. The mixture was heated to 90°C and a solution of p-nitrobenzene sulphonyl chloride (94.3g, 425.4mmol) in toluene (250ml) was added over 30 minutes then stirred for a further 2 hours. The resultant solution of the nosylated intermediate { (1S,2R)-tert-butyl N-[1-benzyl-2-hydroxy-3-(N-isobutyl-4-
10 nitrobenzenesulphonamido)propyl] carbamate } was then cooled to 80°C. The solution was maintained at approximately 80°C, and concentrated hydrochloric acid (31.4ml, 376.8mmol) was added over 20 minutes. The mixture was heated to reflux (approx 86°C) and maintained at this temperature for an hour then a further quantity of concentrated hydrochloric acid (26.4ml, 316.8mmol) was added. Solvent (water
15 and toluene mixture) was removed from the reaction mixture by azeotropic distillation (total volume of solvent removed approx 600ml), and the resultant suspension was cooled to 70-75°C. Denatured ethanol (600ml) was added, and the solution was cooled to 20°C. The mixture was further cooled to approximately -10°C and the precipitate formed was isolated by filtration, washed with denatured ethanol
20 (50ml) and dried at approximately 50°C, under vacuum, for approximately 12 hours, to give (2R,3S)-N-(3-amino-2-hydroxy-4-phenylbutyl)-N-isobutyl-4-nitrobenzene sulphonamide hydrochloride (160g; 73% of theory yield corrected for assay).
NMR: ¹H NMR (300Mhz, dmso-d₆): 8.37(2H, d, J=9Hz), 8.16(NH₃⁺, s), 8.06(2H, d, J=9Hz), 7.31(5H, m), 5.65(1H, d, J=5Hz), 3.95(1H, m), 3.39(2H, m), 2.95(5H, m),
25 1.90(1H, m), 0.77(6H, dd, J=21Hz and 6Hz).

1,1'-carbonyldiimidazole (27.66kg, 170.58mol) was added to ethyl acetate (314.3kg) with stirring to give 3-(S)-tetrahydrofuryl imidazole-1-carboxylate. (S)-3-hydroxytetrahydrofuran (157kg, 178.19mol) was added over 30 minutes, washed in
30 with ethyl acetate (9.95kg), then the mixture was stirred for a further hour. (2R,3S)-N-(3-amino-2-hydroxy-4-phenylbutyl)-N-isobutyl-4-nitrobenzene sulphonamide hydrochloride (65.08kg, 142.10mol) was added and the mixture heated to reflux for approximately 22 hours. The solution was cooled slightly, and denatured ethanol (98 l) was added. The solution was stirred at 60°C for 10 minutes
35 then cooled and the product allowed to crystallise. The mixture was cooled to <10°C

and stirred for 2 hours. The product was isolated by filtration, washed with denatured ethanol (33 l) and dried at approximately 50°C, under vacuum to give (3S)-tetrahydro-3-furyl *N*-[(1S,2R)-1-benzyl-2-hydroxy-3-(*N*-isobutyl-4-nitrobenzene sulphonamido)propyl] carbamate in a yield of 82% of theory.

5 NMR: ¹H NMR (500Mhz, dmso-d₆): 8.38(2H, d, J=9Hz), 8.06(2H, d, J=9Hz), 7.20(6H, m), 5.02(1H, d, J=5Hz), 4.94(1H, m), 4.35(EtOH, broad s), 3.71(EtOH, q), 3.65(1H, m), 3.60(1H, m), 3.51(2H, broad m), 3.40(2H, m), 3.15(1H, dd, J=8Hz and 14Hz), 3.07(1H, dd, J=8Hz and 15Hz), 2.94(2H, m), 2.48(1H, m), 2.06(1H, m), 1.97(1H, m), 1.78(1H, m), 1.05(EtOH, t), 0.83(6H, dd, J=7Hz and 16Hz).

10

Product from the above stage (80.0g, 149.4mmol) was hydrogenated in isopropanol (880ml) with 5% palladium on carbon (16g, of a wet paste) and hydrogen pressure (approx 0.5 to 1.5 bar) at 25-50°C for approximately 5 hours. The mixture was cooled and the catalyst removed by filtration. The solution was distilled to a volume
15 of approximately 320ml and water (80ml) was added. This solution was divided into two for the crystallisation step.

To half of the above solution, decolourising charcoal (2g) was added, the mixture stirred at approximately 32°C for 4 hours, then filtered. The filtercake was washed
20 with isopropanol (20ml) then further water (40ml) was added to the filtrate. The solution was seeded to induce crystallisation and stirred for 5 hours. Water (130ml) was added slowly over 1 hour then the mixture was stirred for 4 hours. The resultant slurry was cooled to approximately 20°C and the product was isolated by filtration and washed with a 1:4 mixture of isopropanol/water (120ml). The product was
25 dried at approximately 50°C, under vacuum, for approximately 12 hours to give (3S)-tetrahydro-3-furyl *N*-[(1S,2R)-3-(4-amino-*N*-isobutylbenzenesulphonamido)-1-benzyl-2-hydroxypropyl] carbamate (30.3g; 80% of theory yield).

NMR: ¹H NMR (300Mhz, dmso-d₆): 7.39(2H, d, J=9Hz), 7.18(6H, m), 6.60(2H, d, J=9Hz), 6.00(2H, s), 4.99(1H, d, J=6Hz), 4.93(1H, ddt), 3.64(5H, m), 3.34(1H, m),
30 3.28(1H, dd, J=14Hz and 3Hz), 3.01(1H, m, J=14Hz and 3Hz), 2.91(1H, m), 2.66(2H, m), 2.50(1H, m), 2.05(1H, m), 1.94(1H, m), 1.78(1H, m), 0.81(6H, dd, J=16Hz and 7Hz).

m/z: 506.2 (M + H⁺)

Example 2

Alternative Preparation of (2R,3S)-N-(3-amino-2-hydroxy-4-phenylbutyl)-N-5 isobutyl-4-nitrobenzene sulphonamide hydrochloride

(1S,2R)-tert-butyl N-[1-benzyl-2-hydroxy-3-(isobutylamino)propyl] carbamate (212.1kg, 630.36mol) was stirred in dimethylacetamide (259.1kg) at 40°C and triethylamine (70.9kg, 700.66mol) was added. A solution of p-nitrobenzene sulphonyl chloride (153.6kg, 693.08mol) in tetrahydrofuran (205.3kg) was added over 2 hours 35 mins, then stirred for a further hour, maintaining the reaction temperature at 40°C. The mixture was cooled to 30°C and water (1079 l) was added to the resultant solution. The solution was then cooled to 25°C. The mixture was stirred for 1 hour then the product was isolated by filtration, washed with water 15 (332 l) and then denatured ethanol (664 l) to give damp (1S,2R)-tert-butyl N-[1-benzyl-2-hydroxy-3-(N-isobutyl-4-nitrobenzene-sulphonamido)propyl] carbamate (618 kg).

NMR: ¹H NMR (500Mhz, dmso-d₆): 8.36(2H, d, J=9Hz), 8.05(2H, d, J=9Hz), 7.18(5H, m), 6.67(1H, d, J=9Hz), 5.02(1H, broad s), 3.63(3H, broad m), 3.63(EtOH, broad s), 3.58(THF, broad m), 3.44(EtOH, q), 3.10(2H, m), 2.93(2H, m), 2.93(DMA, s), 2.78(DMA, s), 2.48(1H, m), 1.97(1H, m), 1.95(DMA, s), 1.74(THF, m), 1.23(9H, s), 1.18(TEA HCl, t), 1.05(EtOH, t), 0.82(6H, dd, J=6Hz and 12Hz)

The damp product of the above stage (602.5kg, 423.9mol corrected for solvent content) was stirred in denatured ethanol (1646 l) and concentrated hydrochloric acid (104.6kg) was added. The mixture was heated to reflux and maintained at this temperature for 3 hours. The solution was then cooled to approximately 35°C and seeded, then cooled further to -5°C to complete the crystallisation. The product was isolated by filtration, washed with denatured ethanol (221.7 l) and dried at 30 approximately 50°C, under vacuum, for approximately 6 hours to give (2R,3S)-N-(3-amino-2-hydroxy-4-phenylbutyl)-N-isobutyl-4-nitrobenzene sulphonamide hydrochloride (153.8kg; 80% of theory yield).

NMR: ¹H NMR (500Mhz, dmso-d₆): 8.37(2H, d, J=9Hz), 8.18(NH₃⁺, s), 8.06(2H, d, J=9Hz), 7.31(5H, m), 5.63(1H, d, J=5Hz), 3.93(1H, m), 3.45(1H, m), 3.39(1H, dd,

J=4Hz and 15Hz), 3.06(2H, m), 2.98(1H, m), 2.87(2H, m), 1.90(1H, m), 0.77(6H, dd, J=21Hz and 6Hz)

The product of the above stage may be used to form the compound of formula (I) in a similar manner to that described in example 1 above.

Example 3

Alternative Preparation of (2R,3S)-N-(3-amino-2-hydroxy-4-phenylbutyl)-N-isobutyl-4-nitrobenzene sulphonamide hydrochloride


(1S,2R)-*Tert*-butyl N-[1-benzyl-2-hydroxy-3-(N-isobutyl-4-nitrobenzene sulphonamido)propyl]carbamate (18kg, 34.5mol; prepared in a similar manner to that described in Example 2) was dried, then stirred in ethyl acetate (62.6kg) at 15 15°C. Hydrogen chloride gas (approx 9kg) was bubbled into the mixture and the reaction stirred below 40°C for approximately 4 hours. The reaction was cooled to approximately 5°C. The product was isolated by filtration, washed with cold ethyl acetate (20 l) then with methyl *tert*-butyl ether (37.8 l), and dried at approximately 50°C under vacuum for approximately 12 hours to give (2R,3S)-N-(3-amino-2- 20 hydroxy-4-phenylbutyl)-N-isobutyl-4-nitrobenzene sulphonamide hydrochloride (13.6kg; 86% of theory yield).

The product of the above stage may be used to form the compound of formula (I) in a similar manner to that described in example 1 above.

CLAIMS


1. A process for the preparation of the compound of formula (I)

5



comprising:

- 10 i) reacting a p-nitrophenylsulfonyl group with a compound of formula (A)



- 15 in which P is an amine-protecting group;
 ii) deprotecting the resultant compound of step i);
 iii) reacting the resultant compound of step (ii) with a tetrahydrofuryloxy carbonyl group; or reacting the resultant compound of step ii) with phosgene, or
 20 equivalent, and reacting the resultant intermediate with (S)-tetrahydro-3-furanol;
 and
 iv) reducing the resultant compound of step iii) to form a compound of formula (I).

- 2) A process as claimed in claim 1 in which the protecting group P in the compound of formula (A) is an alkyl, aryl, benzyl or hetero carbamate, alkyl or aryl amide, or silyl group.
- 5 3) A process as claimed in claim 2 in which the protecting group P in the compound of formula (A) is t-butyl carbamate.
- 4) A process as claimed in any preceding claim in which the p-nitrophenylsulfonyl group in step i) is a p-nitrophenylsulfonyl halide.
- 10 5) A process as claimed in any preceding claim in which step i) is carried out in dimethylacetamide or toluene.
- 6) A process as claimed in any preceding claim in which step ii) is carried out in
15 ethanol or toluene.
- 7) A process as claimed in any preceding claim in which the step ii) product is crystallised as a solvate.
- 20 8) A process as claimed in any preceding claim in which step iii) is carried out by reacting (S)-tetrahydro-3-furanol with 1,1'-carbonyldiimidazole and the step ii) product in a single step.
- 9) A process as claimed in claim 8 in which step iii) is carried in ethyl acetate.
- 25 10) A process as claimed in any preceding claim in which step iv) is carried out by treating the step iii) product with palladium under a hydrogen atmosphere.
- 11) A process as claimed in claim 10 in which step iv) is carried out in
30 isopropanol.
- 12) The compound (2R,3S)-N-(3-amino-2-hydroxy-4-phenylbutyl)-N-isobutyl-4-nitrobenzene sulphonamide hydrochloride and solvates thereof.

INTERNATIONAL SEARCH REPORT

Internat. Application No.
PCT/GB 99/00852

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C07D307/20		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) IPC 6 C07D		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 94 05639 A (VERTEX PHARMACEUTICALS INC.) 17 March 1994 cited in the application see claims; example 168 ---	1-12
Y	MALIGRES, P.E. ET. AL.: "Nosylaziridines. Activated Aziridine Electrophiles." TETRAHEDRON LETTERS, vol. 38, no. 30, 1997, pages 5253-6, XP004083291 Oxford, GB see page 5256, paragraph 2 --- <div style="text-align: right;">-/--</div>	1-12
<div style="display: flex; justify-content: space-between;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex. </div>		
* Special categories of cited documents :		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>*B* document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search <div style="text-align: center;">15 June 1999</div>		Date of mailing of the international search report <div style="text-align: center;">28/06/1999</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer <div style="text-align: center;">Helps, I</div>

INTERNATIONAL SEARCH REPORT

Interns Application No

PCT/GB 99/00852

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>KNIFE, A.C. ET. AL.: "Kinetics of Desulphonative Double Smiles Rearrangement of N-(2-Hydroxyalkyl)-p-nitrobenzenesulphonamides." JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 2, vol. 1976, 1976, pages 1741-8, XP002105885 Oxford, GB see page 1742, Experimental Section -----</p>	1-12

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 99/00852

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9405639 A	17-03-1994	AP 390 A	02-08-1995
		AT 178598 T	15-04-1999
		AU 691160 B	14-05-1998
		AU 4852093 A	29-03-1994
		BG 99540 A	30-11-1995
		CA 2143208 A	17-03-1994
		CN 1087347 A	01-06-1994
		CZ 9500587 A	13-12-1995
		DE 69324369 D	12-05-1999
		EP 0659181 A	28-06-1995
		EP 0885887 A	23-12-1998
		FI 951059 A	18-04-1995
		HU 71892 A	28-02-1996
		JP 8501299 T	13-02-1996
		LT 917 A, B	25-11-1994
		NO 950876 A	08-05-1995
		NZ 256238 A	24-04-1997
		NZ 314376 A	28-10-1998
		PL 307858 A	26-06-1995
		SG 43862 A	14-11-1997
		SK 29395 A	13-09-1995
		US 5585397 A	17-12-1996
		US 5783701 A	21-07-1998
		US 5723490 A	03-03-1998
		US 5856353 A	05-01-1999